Stockscreener 앱 받기
48.66
1.28%
-0.63
시간 외 거래:
48.85
0.19
+0.39%
전일 마감가:
$49.29
열려 있는:
$49.32
하루 거래량:
3.79M
Relative Volume:
1.91
시가총액:
$5.82B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-9.251
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
-4.83%
1개월 성능:
+28.59%
6개월 성능:
+11.99%
1년 성능:
-12.48%
1일 변동 폭
$47.96
$49.32
1주일 범위
$47.34
$51.71
52주 변동 폭
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
48.66 | 5.90B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics, Incorporated $CYTK Shares Acquired by Mirador Capital Partners LP - MarketBeat
Aug Breakouts: Is Cytokinetics Incorporated trading at a discount2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - khodrobank.com
Moving Averages: Is Blue Owl Capital Inc.’s ROE strong enough2025 Breakouts & Breakdowns & Verified Short-Term Plans - khodrobank.com
Cytokinetics (NASDAQ:CYTK) CEO Sells $248,850.00 in Stock - MarketBeat
E. Ohman J or Asset Management AB Buys 77,806 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Intech Investment Management LLC Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17 - Bluefield Daily Telegraph
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK - GlobeNewswire Inc.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action - Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Morningstar
CYTK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Cytokinetics, Incorporated Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 17, 2025 to Discuss Your RightsCYTK - PR Newswire
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated InvestorsLead Plaintiff Deadline November 17, 2025 - ACCESS Newswire
Cytokinetics Investor Sues Over Heart Drug Approval Claims - Law360
Cytokinetics, Inc. Investigated by the Portnoy Lawfirm - GlobeNewswire
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
What are the future prospects of Cytokinetics IncorporatedTrade Entry Report & AI Enhanced Execution Alerts - khodrobank.com
CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Law Offices of Howard G. Smith Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire About Securities Fraud Class Action - MarketScreener
United Services Automobile Association Invests $331,000 in Cytokinetics, Incorporated $CYTK - MarketBeat
Investors Urged to Contact Levi & Korsinsky for Information Before November 17, 2025Cytokinetics, Incorporated (CYTK) - Newsfile
Cytokinetics, Incorporated (CYTK) LawsuitInvestors Urged to Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Cytokinetics announces inducement grants - MarketScreener
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Is Cytokinetics Incorporated affected by consumer sentimentMarket Trend Report & Fast Entry and Exit Trade Plans - khodrobank.com
Cytokinetics Investor Sues Over Heart Drug’s FDA Approval Delay - Bloomberg Law News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Bluefield Daily Telegraph
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has B - GuruFocus
Growth Value: Will Cytokinetics Incorporated outperform its industry peersQuarterly Portfolio Report & AI Based Trade Execution Alerts - khodrobank.com
Cytokinetics (CYTK) Drops on $650-Million Debt Issuance - Yahoo Finance
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholders Filed a Lawsuit Against Cytokinetics for Misleading FDA Timeline - TradingView
Cytokinetics ($CYTK) Delayed Drug Review Due to Incomplete FDA Submission Case - TradingView
Cytokinetics to Present Key Findings on Aficamten at HFSA Annual Scientific Meeting 2025 - Quiver Quantitative
Cytokinetics announces three upcoming presentations at the HFSA Annual Scientific Meeting 2025 - MarketScreener
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 - Yahoo Finance
Levi & Korsinsky Notifies Cytokinetics, Incorporated (CYTK) Shareholders of Class Action Lawsuit and November 17, 2025 Deadline - ACCESS Newswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment stock outlook - Investing.com
Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets a Lead Plaintiff Deadline of November 17, 2025 - GlobeNewswire
X4 Pharmaceuticals restructures; Cytokinetics targets $650M raise - Endpoints News
Cytokinetics (CYTK) Rises on Convertible Note Offering Plan - GuruFocus
Cytokinetics rises after upsized $650 mln convertible bonds sale - TradingView
Woodline Partners LP Grows Stock Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Prices Upsized $650 Million Private Convertible Notes Offering - MarketScreener
Cytokinetics Upsizes Convertible Notes Offering To $650 Mln - Nasdaq
Cytokinetics (CYTK) Boosts Convertible Note Offering to $650M - GuruFocus
Cytokinetics prices $650 million convertible notes offering By Investing.com - Investing.com Canada
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes - The Manila Times
Cytokinetics Inc prices its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 - MarketScreener
$650 Million Debt Refinancing: Cytokinetics Slashes Interest Rate to 1.75% in Strategic Note Offering - Stock Titan
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Sep 09 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 09 '25 |
Sale |
51.29 |
2,000 |
102,580 |
140,610 |
| Kaye Edward M. MD | Director |
Sep 02 '25 |
Sale |
50.00 |
6,756 |
337,800 |
23,230 |
1.43%
0.09%
자본화:
|
볼륨(24시간):